«Hialuronato sódico en el tratamiento de la osteoartritis de tobillo: Estudio piloto doble ciego, aleatorizado y controlado.»
Robert S. Salk, DPM1, Thomas J. Chang, DPM1, Walter F. D’Costa, DPM2, David J. Soomekh, DPM3 and Kirk A. Grogan, DPM1
1 45 Castro Street, Suite #315, San Francisco, CA 94114. E-mail address for R. Salk: email@example.com. E-mail address for T. Chang: firstname.lastname@example.org. E-mail address for K. Grogan: email@example.com 2 2281 Cleveland Avenue, Santa Rosa, CA 95403. E-mail address: firstname.lastname@example.org 3 2121 Wilshire Boulevard, Suite #101, Santa Monica, CA 90403. E-mail address: email@example.com
Investigation performed at the Northern California Foot and Ankle Center, San Francisco and Santa Rosa, California
A commentary is available with the electronic versions of this article, on our web site (www.jbjs.org) and on our quarterly CD-ROM (call our subscription department, at 781-449-9780, to order the CD-ROM).
Note: The authors thank Sara Dahle, MPH, and Huong Le, MPH, for their assistance in statistical analysis.
In support of their research for or preparation of this manuscript, one or more of the authors received grants or outside funding from Sanofi-Aventis, Inc. None of the authors received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, educational institution, or other charitable or nonprofit organization with which the authors are affiliated or associated.
Background: Intra-articular injections of hyaluronans have been shown to be safe and effective for the treatment of pain associated with osteoarthritis of the knee. This pilot study was undertaken to gather preliminary data on the efficacy and safety of five weekly intra-articular injections of Hyalgan (sodium hyaluronate; molecular weight, 500 to 730 kDa) as compared with saline solution for the treatment of pain associated with osteoarthritis of the ankle. Methods: Twenty patients at two test sites were randomized with use of a double-blind (blinded observer), saline solution-controlled, parallel experimental design. Patients were randomized to receive five weekly intra-articular injections of either 1 mL of sodium hyaluronate (10 mg/mL) or 1 mL of phosphate-buffered saline solution into the ankle joint. The primary outcome measurement was the ankle osteoarthritis score. Several secondary outcome measures also were assessed.
Results: Significant improvement in the mean ankle osteoarthritis score from baseline was seen at all follow-up visits from one to six months in both the sodium hyaluronate group and the saline solution group (p < 0.0001). In addition, five of nine patients in the sodium hyaluronate group had >30 mm of improvement in this score, compared with one of eight patients in the control group. No withdrawals were directly attributable to the injections of sodium hyaluronate or saline solution, and no severe medication-related adverse events were observed.
Conclusions: The present study suggests that five weekly intra-articular injections of sodium hyaluronate (molecular weight, 500 to 730 kDa) are well tolerated, can provide sustained relief of pain, and can improve function in patients with osteoarthritis of the ankle. These findings are consistent with those of previously published studies involving intra-articular injections of sodium hyaluronate in other joints, but they require confirmation in a large, randomized, saline solution-controlled study.
The Journal of Bone and Joint Surgery (American). 2006;88:295-302.